The U.S. Department of Justice is accusing local drug maker Regeneron of fraudulent drug pricing.

The department has filed a False Claims Act complaint against Regeneron Pharmaceuticals, claiming the company filed false average sales price reports.

The complaint accuses the Renssealer-based company of failing to report price concession on its drug Eylea, which is used to treat neovascular age-related macular degeneration.

The government alleges Regeneron then greatly inflated the costs of its drug to Medicare over many years and enhanced its revenues.